6:2 Chlorinated Polyfluoroalkyl Ether Sulfonates Exert Stronger Thyroid Homeostasis Disruptive Effects in Newborns than Perfluorooctanesulfonate: Evidence Based on Bayesian Benchmark Dose Values from a Population Study.
6:2 Chlorinated Polyfluoroalkyl Ether Sulfonates Exert Stronger Thyroid Homeostasis Disruptive Effects in Newborns than Perfluorooctanesulfonate: Evidence Based on Bayesian Benchmark Dose Values from a Population Study.
复制标题
DOI：
10.1021/acs.est.3c03952
复制
发表时间：
2023-07
影响因子：
11.4
通讯作者：
Xin Liu;Lei Zhang;Jiaying Liu;Gerili Zaya;Yuxin Wang;Qian Xiang;Jingguang Li;Yongning Wu-
中科院分区：
文献类型：
--
作者：
Xin Liu;Lei Zhang;Jiaying Liu;Gerili Zaya;Yuxin Wang;Qian Xiang;Jingguang Li;Yongning Wu-
越来越多的毒理学证据表明，新出现的全氟烷基物质（PFAS），如氯化多氟烷基醚磺酸盐（Cl-PFESA），可能与全氟辛烷磺酸盐（PFOS）和全氟辛酸（PFOA）一样有毒或毒性更大。然而，在人类健康风险评估方面需要进一步的调查。该研究检查了新出现的和遗留的全氟辛烷磺酸暴露对新生儿甲状腺稳态的影响，并使用基准剂量方法比较了6：2 Cl-PFESA和全氟辛烷磺酸对甲状腺的破坏。分别采用偏最小二乘（PLS）模型和线性回归估计混合暴露和个体暴露的健康效应。贝叶斯基准剂量分析确定了6：2 Cl-PFESA和全氟辛烷磺酸之间进行不利影响比较的BMD值。发现6：2 Cl-PFESA（0.573 [0.351-0.872]纳克/毫升）、全氟辛烷磺酸（0.674 [0.462-1.007]纳克/毫升）和全氟辛酸（1.457 [1.034，2.405]纳克/毫升）的中位（四分位距）浓度相似。偏最小二乘法模型对全氟辛烷磺酸变量的预测重要性评分排序如下：6：2 Cl-PFESA > PFOS > PFOA。线性回归显示，6：2 Cl-PFESA与游离三碘甲状腺原氨酸（FT 3，P = 0.006）和三碘甲状腺原氨酸（T3，P = 0.014）呈正相关，而全氟辛烷磺酸与单独的FT 3呈轻微显著正相关（P = 0.042）。骨密度分析表明，6：2 Cl-PFESA（1.01纳克/毫升）的BMD 10估计值低于全氟辛烷磺酸（1.66纳克/毫升），与FT 3增加10%有关。这些研究结果表明，与全氟辛烷磺酸和其他遗留的全氟辛烷磺酸相比，6：2 Cl-PFESA（全氟辛烷磺酸的替代品）对新生儿甲状腺体内平衡的影响更为显著。
Growing toxicologic evidence suggests that emerging perfluoroalkyl substances (PFASs), like chlorinated polyfluoroalkyl ether sulfonate (Cl-PFESA), may be as toxic or more toxic than perfluorooctanesulfonate (PFOS) and perfluorooctanoic acid (PFOA). However, further investigations are needed in terms of the human health risk assessment. This study examined the effects of emerging and legacy PFAS exposure on newborn thyroid homeostasis and compared the thyroid disruption caused by 6:2 Cl-PFESA and PFOS using a benchmark dose approach. The health effects of mixture and individual exposure were estimated using the partial least-squares (PLS) model and linear regression, respectively. A Bayesian benchmark dose (BMD) analysis determined the BMD value for adverse effect comparison between 6:2 Cl-PFESA and PFOS. The median (interquartile range) concentrations of 6:2 Cl-PFESA (0.573 [0.351-0.872] ng/mL), PFOS (0.674 [0.462-1.007] ng/mL), and PFOA (1.457 [1.034, 2.405] ng/mL) were found to be similar. The PLS model ranked the PFAS variables' importance in projection (VIP) scores as follows: 6:2 Cl-PFESA > PFOS > PFOA. Linear regression showed that 6:2 Cl-PFESA had a positive association with free triiodothyronine (FT3, P = 0.006) and triiodothyronine (T3, P = 0.014), while PFOS had a marginally significant positive association with FT3 alone (P = 0.042). The BMD analysis indicated that the estimated BMD10 for 6:2 Cl-PFESA (1.01 ng/mL) was lower than that for PFOS (1.66 ng/mL) in relation to a 10% increase in FT3. These findings suggest that 6:2 Cl-PFESA, an alternative to PFOS, has a more pronounced impact on newborns' thyroid homeostasis compared to PFOS and other legacy PFASs.